Problem Elective PCI for all reasons
Format Single-center randomised single-blinded (patient) controlled trial
Treatment Everolimus-eluting stent
Control Piclitaxel-eluting stent
Population 1800 patients
Inclusion criteria Consecutive patients, between 18 and 85 years of age, referred to Maasstad Ziekenhuis for elective or emergent percutaneous coronary intervention were eligible to participate. There were no limitations on the number of lesions or vessels, the location of lesions, or their length.
Exclusion criteria Major exclusion criteria were contraindications to or expected nonadherence to dual antiplatelet therapy (DAPT) in the 12 months after the procedure, planned major surgery within 30 days, and inability to give informed consent.
Follow-up 2 years
Primary endpoint Composite of all death, myocardial infarction (MI), and target vessel revascularization (TVR) at 12 months
Secondary endpoint(s) Primary composite endpoint at 2-year follow-up
Composite of major adverse cardiac events (cardiac death, nonfatal MI, and clinically driven TLR at 2-year follow-up).
Details .
Brief summary: Everolimus-eluting (2nd generation) stents reduced MACE and stent thrombosis even with reduced DAPT therapy at 2 years (versus 1st generation stent)
PAPER: 2-year follow-up of a randomized controlled trial of everolimus- and paclitaxel-eluting stents for coronary revascularization in daily practice. COMPARE
Date 28 Jun 2011
Journal J Am Coll Cardiol. 2011 Jun 28;58(1):11-8. doi: 10.1016/j.jacc.2011.02.023.
Information Everolimus-eluting stent (2nd generaton) versus piclitaxel-eluting stent (1st gen)
-Single center single-blinded (patient) trial
--Including elective and ACS patients
-Reduced MACE
-Reduced in-stent thrombosis
-Even at 2 years after DAPT stopped
--DAPT less common in everolimus arm at this time